Otonomy, Inc. (OTIC) Rating Reiterated by Piper Jaffray Companies
Piper Jaffray Companies reiterated their hold rating on shares of Otonomy, Inc. (NASDAQ:OTIC) in a report published on Friday. The brokerage currently has a $8.00 price target on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently issued reports on the stock. SunTrust Banks, Inc. reaffirmed a buy rating and set a $15.00 price target (down previously from $45.00) on shares of Otonomy in a research note on Thursday, August 31st. J P Morgan Chase & Co downgraded shares of Otonomy from an overweight rating to a neutral rating and decreased their price target for the company from $28.00 to $8.00 in a research note on Wednesday, August 30th. Cowen and Company reaffirmed an outperform rating and set a $9.00 price target (down previously from $55.00) on shares of Otonomy in a research note on Thursday, August 31st. ValuEngine downgraded shares of Otonomy from a sell rating to a strong sell rating in a research note on Friday, September 1st. Finally, Zacks Investment Research raised shares of Otonomy from a sell rating to a hold rating in a research note on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $10.00.
Shares of Otonomy (NASDAQ OTIC) opened at $5.20 on Friday. Otonomy has a 12 month low of $2.80 and a 12 month high of $21.15.
Otonomy (NASDAQ:OTIC) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.15. The company had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.43 million. Otonomy had a negative net margin of 7,899.03% and a negative return on equity of 60.74%. The business’s revenue was down 12.8% on a year-over-year basis. equities research analysts expect that Otonomy will post -3 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Otonomy, Inc. (OTIC) Rating Reiterated by Piper Jaffray Companies” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/14/otonomy-inc-otic-rating-reiterated-by-piper-jaffray-companies.html.
Institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in shares of Otonomy in the second quarter valued at $115,000. Legal & General Group Plc raised its stake in shares of Otonomy by 13.3% in the second quarter. Legal & General Group Plc now owns 6,348 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 746 shares during the period. Voya Investment Management LLC raised its stake in shares of Otonomy by 17.9% in the second quarter. Voya Investment Management LLC now owns 12,606 shares of the biopharmaceutical company’s stock valued at $238,000 after acquiring an additional 1,918 shares during the period. American International Group Inc. raised its stake in shares of Otonomy by 7.1% in the first quarter. American International Group Inc. now owns 14,800 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 981 shares during the period. Finally, Tudor Investment Corp ET AL purchased a new stake in shares of Otonomy in the first quarter valued at $216,000. 78.12% of the stock is currently owned by institutional investors and hedge funds.
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.